Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects

British Journal of Clinical Pharmacology, Supplement

Volumn 52, Issue 3, 2001, Pages 297-305

  Klinkhardt, Ute ^a   Graff, Jochen ^a   Westrup, Dagmar ^b   Kirchmaier, Carl M ^b   Esslinger, Hans Ulrich ^c   Breddin, Hans Klaus ^d   Harder, Sebastian ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c Knoll AG   (Germany)

^d International Institute of Thrombosis and Vascular Diseases   (Germany)

Author keywords

Aspirin; GPIIb IIIa antagonists; Heparin; Interaction

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; DRUG DERIVATIVE; FIBRINOGEN; FIBRINOGEN RECEPTOR; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; REVIPARIN; SELECTIN; TIROFIBAN; TYROSINE;

ADOLESCENT; ADULT; ARTICLE; BINDING COMPETITION; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; FLOW CYTOMETRY; HUMAN; MALE; METABOLISM; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BINDING, COMPETITIVE; BLEEDING TIME; BLOOD PLATELETS; DRUG INTERACTIONS; FACTOR XA; FIBRINOGEN; FLOW CYTOMETRY; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SELECTINS; TREATMENT OUTCOME; TYROSINE;

EID: 0035458685     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01446.x     Document Type: Article

References (37)

1. Topol EJ, Byzova TV, Plow ER. Platelet GPIIb/IIIa blockers. Lancet 1999; 353: 227-231.
2. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein Ilb/IIIa integrin in ischémie heart disease. Circulation 1998; 98: 2829-2835.
3. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
4. Brener SJ, on behalf of the ReoPro and Primary PTCA Organzation and Randomized Trial (RAPPORT) Investigators. Randomized, placebo controlled trial of platelet glycoprotein Ilb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-741.
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
6. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.
7. Mikhailidis DP, Fonseca VA, Barradas MA, Jeremy JY, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pliannacol 1987; 24: 415-424.
8. Leroy J, Leclerc MH, Elahousse B. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216). Seminar Tliromb Hacmost 1985; 11: 326-329.
9. Westwick J, Scully MF, Poll C, Kakkar VV. Comparison of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Tliromb Res 1986; 42: 435-447.
10. Reverter JC, Béguin S, Kessels H, Kuniar R, Hemker HC, Coller BS. Inhibition of platelet mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'._/ Clin Invest 1996; 98: 863-874.
11. Harder S, Kirchmaier CM, Krzywanek J, Westrup D, Bae JW, Breddin HK. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein Ilb/IIIa inhibitor (YM 337) in healthy subjects. Circulation 1999; 100: 1175-1182.
12. Rao AK, Sun L, Hiramatsu Y, Gorman JH 3rd, Edmunds LH Jr. Glycoprotein Ilb/IIIa receptor antagonists tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons. Tliromb Hacmost 1999; 82: 140-144.
13. Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alpha2/beta3 binds prothrombin and influences its activation. J Biol Client 1997; 272: 27183-27188.
14. Amman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-1608.
15. Amman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 1113 trial. Circulation 1999; 100: 1593-1601.
16. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996; 28: 1437-1443.
17. Armstrong PW. Pursuing progress in acute coronary syndromes. Circulation 1999; 100: 1586-1589.
18. Kennedy JW, Stadius ML. Combined thrombolytic and platelet glycoprotein Ilb/IIIa inhibitor therapy for acute myocardial infarction: will pharmacological therapy ever equal primary angioplasty? Circulation 1999; 99: 2714-2716.
19. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273-281.
20. Jeske W, Farced J, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A. Biochemical and pharmacologie characteristics of Reviparin, a low-molecular-mass heparin. Scmin Tliromb Hemost 1997; 23: 119-128.
21. Azizi M, Veyssier-Belot C, Alhenc-Gelas M, et al. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br J Clin Pharmacol 1995; 40: 577-584.
22. Planes A. Comparison of antithrombotic efficacy and haemorrhagic side-effects of reviparin-sodium versus enoxiparin in patients undergoing total hip replacement. Blood Coagulation Fibrinolysii 1993; 4: 33-35.
23. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994; 123: 728-740.
24. Verbeugt FW, Becker RC, Bertrand ME, et al. Management strategies in unstable coronary artery disease - current problems and future directions. The UCAD Council. Clin Cardiol 1999; 22: 551-553.
25. Kitchen S, lampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Tliromb Hacnwst 1999; 82: 1289-1293.
26. Chen J, Karlberg KE, Sylvén C. Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers. Thromb Res 1991; 63: 319-329.
27. Chen J, Sylvén C. Heparin potentiation of collagen-induced platelet aggregation is related to the GPIIbIIIa receptor and not to the GPIb receptor, as tested by whole blood aggregometry. Thromb Res 1992; 66: 111-120.
28. Fernandez F, N'guyen P, Van Ryn J. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-495.
29. Mascelli MA, Kleiman NS, Marciniak SJJr, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologie assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 2000; 139: 696-703.
30. Steinhubl SR. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study. J Thromb Thrombolysis 2000; 9: 199-205.
31. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Blood 1990; 75: 550-554.
32. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and ASA pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997; 29: 13-20.
33. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279-285.
34. Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin alpha lib beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 1997; 88: 137-146.
35. Byrne A, Moran N, Maher M, Walsh N, Crean P, Fitzgerald DJ. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol 1997; 17: 3224-3229.
36. Graff J, Andries D, Elsner M, et al. Platelet CD62 expression and PDGF secretion in patients undergoing PTCA and treatment with abciximab. Br J Clin Pharmacol 2001; in press.
37. Klinkhardt U, Kirchmaier CM, Hildt M, et al. Differential in vitro effects of the platelet glycoprotein Ilb/IIIa-inhibitors abciximab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters. Thromb Res 2000; 97: 201-207.